# Relmada Therapeutics, Inc.: financial statements, quarterly

RLMD · Nasdaq · CIK 1553643 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rlmd.md) · [Financials](/companies/rlmd/financials.md) · [Filings](/companies/rlmd/filings.md) · [Insiders](/companies/rlmd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rlmd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [10.5](/filings/0001213900-24-095398.md) | [14.8 d](/filings/0001013762-25-003426.md) | [13.3](/filings/0001213900-25-042025.md) | [10.7](/filings/0001213900-25-073073.md) | [11.1](/filings/0001213900-25-109983.md) | [11.0 d](/filings/0001213900-26-031862.md) | [12.0](/filings/0001213900-26-055059.md) | [2.8](/filings/0001213900-26-086151.md) | [4.0](/filings/0001213900-25-109983.md) | [8.1 d](/filings/0001213900-26-031862.md) | [8.1](/filings/0001213900-26-055059.md) | [8.4](/filings/0001213900-26-086151.md) |
| Operating income | $m | [(22.7)](/filings/0001213900-24-095398.md) | [(26.8) d](/filings/0001013762-25-003426.md) | [(23.0)](/filings/0001213900-25-042025.md) | [(18.8)](/filings/0001213900-25-073073.md) | [(23.0)](/filings/0001213900-25-109983.md) | [(19.1) d](/filings/0001213900-26-031862.md) | [(18.2)](/filings/0001213900-26-055059.md) | [(10.2)](/filings/0001213900-26-086151.md) | [(10.3)](/filings/0001213900-25-109983.md) | [(20.3) d](/filings/0001213900-26-031862.md) | [(19.5)](/filings/0001213900-26-055059.md) | [(15.0)](/filings/0001213900-26-086151.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(22.0)](/filings/0001213900-24-095398.md) | [(25.2) d](/filings/0001013762-25-003426.md) | [(21.8)](/filings/0001213900-25-109983.md) | [(17.8)](/filings/0001213900-25-109983.md) | [(21.7)](/filings/0001213900-25-109983.md) | [(18.7) d](/filings/0001213900-26-031862.md) | [(17.6)](/filings/0001213900-26-086151.md) | [(9.9)](/filings/0001213900-26-086151.md) | [(10.1)](/filings/0001213900-25-109983.md) | [(19.9) d](/filings/0001213900-26-031862.md) | [(19.1)](/filings/0001213900-26-086151.md) | [(12.9)](/filings/0001213900-26-086151.md) |
| Diluted EPS | $ per share | [(0.73)](/filings/0001213900-24-095398.md) | not reported | [(0.72)](/filings/0001213900-25-042025.md) | [(0.59)](/filings/0001213900-25-073073.md) | [(0.72)](/filings/0001213900-25-109983.md) | not reported | [(0.58)](/filings/0001213900-26-055059.md) | [(0.30)](/filings/0001213900-26-086151.md) | [(0.30)](/filings/0001213900-25-109983.md) | not reported | [(0.22)](/filings/0001213900-26-055059.md) | [(0.11)](/filings/0001213900-26-086151.md) |
| Basic EPS | $ per share | [(0.73)](/filings/0001213900-24-095398.md) | not reported | [(0.72)](/filings/0001213900-25-042025.md) | [(0.59)](/filings/0001213900-25-073073.md) | [(0.72)](/filings/0001213900-25-109983.md) | not reported | [(0.58)](/filings/0001213900-26-055059.md) | [(0.30)](/filings/0001213900-26-086151.md) | [(0.30)](/filings/0001213900-25-109983.md) | not reported | [(0.22)](/filings/0001213900-26-055059.md) | [(0.11)](/filings/0001213900-26-086151.md) |

- Revenue: not reported
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [6.7](/filings/0001213900-23-084737.md) | [4.1](/filings/0001013762-25-003426.md) | [1.3](/filings/0001213900-24-040856.md) | [2.1](/filings/0001213900-24-066111.md) | [1.5](/filings/0001213900-24-095398.md) | [3.9](/filings/0001213900-26-031862.md) | [1.1](/filings/0001213900-25-042025.md) | [1.4](/filings/0001213900-25-073073.md) | [1.4](/filings/0001213900-25-109983.md) | [3.5](/filings/0001213900-26-086151.md) | [9.8](/filings/0001213900-26-055059.md) | [11.3](/filings/0001213900-26-086151.md) |
| Current assets | $m | [109](/filings/0001213900-23-084737.md) | [97.5](/filings/0001013762-25-003426.md) | [84.4](/filings/0001213900-24-040856.md) | [71.0](/filings/0001213900-24-066111.md) | [55.7](/filings/0001213900-24-095398.md) | [45.8](/filings/0001213900-26-031862.md) | [27.7](/filings/0001213900-25-042025.md) | [21.1](/filings/0001213900-25-073073.md) | [14.9](/filings/0001213900-25-109983.md) | [94.0](/filings/0001213900-26-086151.md) | [235](/filings/0001213900-26-055059.md) | [219](/filings/0001213900-26-086151.md) |
| Total assets | $m | [109](/filings/0001213900-23-084737.md) | [97.6](/filings/0001013762-25-003426.md) | [84.4](/filings/0001213900-24-040856.md) | [71.0](/filings/0001213900-24-066111.md) | [55.7](/filings/0001213900-24-095398.md) | [45.8](/filings/0001213900-26-031862.md) | [27.7](/filings/0001213900-25-042025.md) | [21.1](/filings/0001213900-25-073073.md) | [14.9](/filings/0001213900-25-109983.md) | [94.0](/filings/0001213900-26-086151.md) | [235](/filings/0001213900-26-055059.md) | [219](/filings/0001213900-26-086151.md) |
| Current liabilities | $m | [8.4](/filings/0001213900-23-084737.md) | [12.2](/filings/0001013762-25-003426.md) | [12.4](/filings/0001213900-24-040856.md) | [9.5](/filings/0001213900-24-066111.md) | [8.1](/filings/0001213900-24-095398.md) | [10.3](/filings/0001213900-26-031862.md) | [5.2](/filings/0001213900-25-042025.md) | [5.1](/filings/0001213900-25-073073.md) | [5.2](/filings/0001213900-25-109983.md) | [6.4](/filings/0001213900-26-086151.md) | [12.9](/filings/0001213900-26-055059.md) | [7.4](/filings/0001213900-26-086151.md) |
| Total liabilities | $m | not reported | [12.2](/filings/0001013762-25-003426.md) | [12.4](/filings/0001213900-24-040856.md) | not reported | [8.1](/filings/0001213900-24-095398.md) | [10.3](/filings/0001213900-26-031862.md) | [5.2](/filings/0001213900-25-042025.md) | [5.2](/filings/0001213900-25-073073.md) | [5.4](/filings/0001213900-25-109983.md) | [7.5](/filings/0001213900-26-086151.md) | [16.6](/filings/0001213900-26-055059.md) | [12.5](/filings/0001213900-26-086151.md) |
| Shareholders' equity | $m | [101](/filings/0001213900-24-095398.md) | [85.4](/filings/0001213900-26-031862.md) | [72.0](/filings/0001213900-25-109983.md) | [61.5](/filings/0001213900-25-109983.md) | [47.6](/filings/0001213900-25-109983.md) | [35.5](/filings/0001213900-26-086151.md) | [22.4](/filings/0001213900-26-086151.md) | [15.9](/filings/0001213900-26-086151.md) | [9.5](/filings/0001213900-25-109983.md) | [86.5](/filings/0001213900-26-086151.md) | [219](/filings/0001213900-26-086151.md) | [207](/filings/0001213900-26-086151.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.6) d](/filings/0001213900-24-095398.md) | [(10.2) d](/filings/0001013762-25-003426.md) | [(13.0)](/filings/0001213900-25-042025.md) | [(13.3) d](/filings/0001213900-25-073073.md) | [(16.7) d](/filings/0001213900-25-109983.md) | [(8.8) d](/filings/0001213900-26-031862.md) | [(18.1)](/filings/0001213900-26-055059.md) | [(6.4) d](/filings/0001213900-26-086151.md) | [(6.7) d](/filings/0001213900-25-109983.md) | [(14.6) d](/filings/0001213900-26-031862.md) | [(15.1)](/filings/0001213900-26-055059.md) | [(9.6) d](/filings/0001213900-26-086151.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [3.4](/filings/0001213900-26-055059.md) | [6.5 d](/filings/0001213900-26-086151.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [30.1](/filings/0001213900-23-084737.md) | [30.1](/filings/0001213900-24-040856.md) | [30.1](/filings/0001213900-24-066111.md) | [30.1](/filings/0001213900-24-095398.md) | [30.1](/filings/0001213900-25-042025.md) | [30.2](/filings/0001213900-25-073073.md) | [30.2](/filings/0001213900-25-109983.md) | [30.4](/filings/0001213900-26-055059.md) | [33.2](/filings/0001213900-26-086151.md) | [33.2](/filings/0001213900-25-109983.md) | [86.6](/filings/0001213900-26-055059.md) | [112](/filings/0001213900-26-086151.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 106,669,846 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001213900-26-086151.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.